Business Context and Reporting Period
This Form 8-K filing by Ultragenyx Pharmaceutical Inc. reports on events occurring on February 27, 2015. The company is a Delaware corporation headquartered in Novato, California. The report specifically addresses Item 5.02 regarding compensatory arrangements for certain officers.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation adjustments effective January 1, 2015:
- Emil D. Kakkis, M.D., Ph.D. (President and CEO): $535,000 annual base salary.
- Thomas R. Kassberg (SVP, Chief Business Officer): $390,000 annual base salary.
- Shalini Sharp (SVP, Chief Financial Officer): $420,000 annual base salary.
Material Changes
The Compensation Committee approved annual base salary increases for the three named officers. These increases were retroactively effective as of January 1, 2015, marking the start of the fiscal year. No other material changes to operations or financial status are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The document is strictly limited to the disclosure of the approved salary adjustments.
Investor Verification Checklist
- Verify the total annual compensation cost impact of these salary increases against the company's cash burn rate.
- Confirm if these salary adjustments were part of a broader compensation plan approved by shareholders.
- Review the company's most recent 10-K or 10-Q for context on overall executive compensation trends and cash position.